Expression and functional mechanism of high mobility group A2 in neoplasm

Abstract

Abstract: The high mobility group A2 (HMGA2), one of nonhistone chromatin protein, can specificly bind to ATrich DNA sequences by its AThook and work as oncofetal gene and architectural transcription factor. HMGA2 expresses in almost all kinds of malignant neoplasms, which is closely related to the formation, development and poor prognosis of the neoplasms. HMGA2 plays a very important role in every biological process including cell proliferation, cell cycle, stem cell selfrenewal, epithelialmesenchymal transition and DNA damage repair. It is of great significance to study the effect and mechanism of HMGA2 in neoplasms.

Key words: HMGA2 protein, Neoplasms, Gene expression, Functional mechanism

LI Qing, LU Ying, ZHANG Chun-Ying, MAO Jun, LI Lian-Hong. Expression and functional mechanism of high mobility group A2 in neoplasm[J]. Journal of International Oncology, 2016, 43(2): 106-.

References

［1］ Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/βcatenin pathway in gastric cancer［J］. Dig Dis Sci, 2013, 58(3): 724733. DOI:10.1007/s1062001223996. ［2］ Kong DQ, Su GQ, Zha L, et al. Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer［J］. Med Oncol, 2014, 31(8): 130139. DOI:10.1007/s1203201401305. ［3］ Wang XC, Liu XY, Li AY, et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers［J］. Clin Cancer Res, 2011, 17(8): 25702580. DOI:10.1158/10780432.CCR102542. ［4］ Wu Y, Song Y, Liu H. Expression and its clinical significance of HMGA2 in the patients with nonsmall cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2008, 11(3): 377381. DOI:10.3779/j.issn.10093419.2008.03.005. ［5］ Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer［J］. Mol Cancer Res, 2008, 6(5): 743750. DOI:10.1158/15417786.MCR070095. ［6］ Kumar MS, ArmenterosMonterroso E, East P, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression［J］. Nature, 2014, 505(7482): 212217. DOI:10.1038/nature12785. ［7］ Califano D, Pignata S, Losito NS, et al. High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer［J］. J Cell Physiol, 2014, 229(1): 5359. DOI:10.1002/jcp.24416. ［8］ Malek A, Bakhidze E, Noske A, et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy［J］. Int J Cancer, 2008, 123(2): 348356. DOI:10.1002/ijc.23491. ［9］ Morishita A, Zaidi MR, Mitoro AA, et al. HMGA2 is a driver of tumor metastasis［J］. Cancer Res, 2013, 73(14): 42894299. DOI:10.1158/00085472.CAN123848. ［10］ Sun M, Song CX, Huang H, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis［J］. Proc Natl Acad Sci USA, 2013, 110(24): 99209925. DOI:10.1073/pnas.1305172110. ［11］ Yang GL, Zhang LH, Bo JJ, et al. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis［J］. Eur J Surg Oncol, 2011, 37(3): 265271. ［12］ Liu B, Pang B, Hou XZ, et al. Expression of highmobility group AThook protein 2 and its prognostic significance in malignant gliomas［J］. Hum Pathol, 2014, 45(8): 17521758. DOI:10.1016/j.humpath.2014.02.028. ［13］ Yamazaki H, Mori T, Yazawa M, et al. Stem cell selfrenewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis［J］. Lab Invest, 2013, 93(12): 13311338. DOI:10.1038/labinvest.2013.120. ［14］ Thuault S, Tan EJ, Peinado H, et al. HMGA2 and smads coregulate SNAIL1 expression during induction of EpithelialtoMesenchymal transition［J］. J Biol Chem, 2008, 283(48): 3343733446. DOI:10.1074/jbc.M802016200. ［15］ Li Y, Zhao ZX, Xu CH, et al. HMGA2 induces transcription factor Slug expression to promote epithelialtomesenchymal transition and contributes to colon cancer progression［J］. Cancer Lett, 2014, 355(1): 130140. DOI:10.1016/j.canlet.2014.09.007. ［16］ Ikeda K, Ogawa K, Takeishi Y. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms［J］. Fukushima J Med Sci, 2012, 58(2): 91100. ［17］ Morshedi A, Ren ZL, Li JM, et al. Probing into the biological processes influenced by ESC factor and oncoprotein HMGA2 using iPSCs［J］. Stem Cell Rev, 2013, 9(4): 514522. DOI:10.1007/s1201501293738. ［18］ Nishino J, Kim I, Chada K, et al. Hmga2 promotes neural stem cell selfrenewal in young but not old mice by reducing p16Ink4a and p19Arf expression［J］. Cell, 2008, 135(2): 227239. DOI:10.1016/j.cell.2008.09.017. ［19］ Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity［J］. Cancer Cell, 2006, 9(6): 459471. DOI:10.1016/j.ccr.2006.04.024. ［20］ De Martino I, Visone R, Wierinckx A, et al. HMGA proteins upregulate CCNB2 gene in mouse and human pituitary adenomas［J］. Cancer Res, 2009, 69(5): 18441850. DOI:10.1158/00085472.CAN084133. ［21］ Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2［J］. Mol Cell Biol, 2003, 23(24): 91049116. DOI:10.1128/MCB.23.24.91049116.2003. ［22］ Yu HJ, Lim HH, Tjokro NO, et al. Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells［J］. Cell Rep, 2014, 6(4): 684697. DOI:10.1016/j.celrep.2014.01.014. ［23］ Li AY, Boo LM, Wang SY, et al. Suppression of nonhomologous end joining repair by overexpression of HMGA2［J］. Cancer Res, 2009, 69(14): 56995706. DOI:10.1158/00085472.CAN084833. ［24］ Borrmann L, Schwanbeck R, Heyduk T, et al. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity［J］. Nucleic Acids Res, 2003, 31(23): 68416851. DOI:10.1093/nar/gkg884. ［25］ Natarajan S, HombachKlonisch S, Droege PA. HMGA2 inhibits apoptosis through interaction with ATRCHK1 signaling complex in human cancer cells［J］. Neoplasia, 2013, 15(3): 263. DOI:10.1593/neo.121988.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.